Drugs Targeting Mechanisms of Aging to Delay Age-Related Disease and Promote Healthspan: Proceedings of a National Institute on Aging Workshop.
Level 5 - mechanism / opinion, no new human data
Workshop proceedings and narrative expert review summarizing preclinical and preliminary human literature without original data or systematic synthesis.
PubMed 37325957 · doi:10.1093/gerona/glad034
What was done
Content experts at a National Institute on Aging workshop conducted literature reviews and state-of-the-field assessments on pharmacological interventions targeting biological mechanisms of aging to extend healthspan. The workshop focused on three classes of agents: senolytics, nicotinamide adenine dinucleotide (NAD+) boosters (including nicotinamide riboside and nicotinamide mononucleotide), and metformin.
What was found
The abstract reports no quantitative data or specific numerical endpoints. Preclinical rodent studies demonstrate that senolytics and NAD+ precursors improve healthspan or extend lifespan in model organisms. Human studies of senolytics are ongoing. Human trials of NAD+ precursors remain limited with mixed results. For metformin, preclinical and observational studies suggest life span extension and lower risk of age-related diseases, with formal clinical trials for healthspan and frailty prevention underway.
Why it matters
This review synthesizes the translational status of major geroscience pharmacotherapies, summarizing the progression from preclinical lifespan extension to human clinical trials aimed at delaying age-related multimorbidity.
Limits
This paper is a narrative conference summary and review, not an empirical study or systematic review with meta-analysis. The abstract reports no quantitative trial outcomes, effect sizes, or safety data. Human clinical evidence across all three drug classes remains preliminary, mixed, or in progress.
Cited by
- supports There are no human interventions tested or validated that have been shown to extend lifespan.